TopFunds

Edwards Lifesciences

NYSE: EW

Stock price

84.24 USD

(+0%) TODAY

Health Care EquipmentMedical - Devices
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
0.8
0.9
1
1.1
1.6
1.3
2.4
2.4
2.3
7
1.8
9.3%
02Free cash flow per share
0.7
0.7
1.3
1.1
1.4
1
2.2
1.5
1
0.5
2.3
13%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
2,494
2,964
3,435
3,723
4,348
4,386
5,233
5,382
5,010
5,440
6,068
9.3%
06% Change
-
-
-
-
-
-
-
-
-
-
-
9.3%
07Cost of revenue
(684.3)
(805.8)
(882.9)
(922.1)
(1,155)
(1,099)
(1,226)
(1,167)
(1,037)
(1,118)
(1,327)
6.9%
08Gross profit
1,809
2,158
2,552
2,801
3,193
3,287
4,007
4,215
3,973
4,322
4,741
10.1%
09% Margin
72.6%
72.8%
74.3%
75.2%
73.4%
74.9%
76.6%
78.3%
79.3%
79.5%
78.1%
75.9% A
10Operating expenses
(1,234)
(1,342)
(1,542)
(1,708)
(1,995)
(1,991)
(2,396)
(2,513)
(2,545)
(2,943)
(3,105)
9.7%
11% of Revenue
(49.5)%
(45.3)%
(44.9)%
(45.9)%
(45.9)%
(45.4)%
(45.8)%
(46.7)%
(50.8)%
(54.1)%
(51.2)%
(47.8)% A
12Operating Income
575.9
815.5
1,010
1,092
1,198
1,296
1,610
1,702
1,427
1,379
1,636
11%
13Income tax expense
(127.5)
(168.4)
(451.3)
(39.2)
(119.6)
(93.3)
(198.9)
(245.5)
(152.4)
(152.1)
(216.9)
5.5%
14Net Income
494.9
569.5
622.1
722.2
1,047
823.4
1,503
1,522
1,402
4,175
1,074
8.1%
15% Margin
19.9%
19.2%
18.1%
19.4%
24.1%
18.8%
28.7%
28.3%
28%
76.8%
17.7%
27.2% A
16Shares Outstanding
660.9
653.4
647.7
640.8
636.6
631.9
631.2
624.2
609.4
599.3
585.8
(1.2)%
17EPS Basic
0.8
0.9
1
1.2
1.7
1.3
2.4
2.5
2.3
7
1.8
9.1%
18EPS Diluted
0.8
0.9
1
1.1
1.6
1.3
2.4
2.4
2.3
7
1.8
9.3%
19EBITDA
706.6
827.1
1,140
872.2
1,308
1,074
1,890
1,960
1,535
1,723
1,430
7.3%
% Margin
28.3%
27.9%
33.2%
23.4%
30.1%
24.5%
36.1%
36.4%
30.6%
31.7%
23.6%
29.6% A
20Net Interest Income (expense)
(10.5)
(7.2)
(2.9)
(1.4)
4.9
1.2
(7.4)
9.3
49.6
100.5
148.4
-
21Net Debt / EBITDA
(0.2)
(0.1)
0.2
(0.1)
(0.4)
(0.5)
(0.1)
-
(0.3)
(1.4)
(1.6)
(0.4) A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
718.4
930.1
818.3
714.1
1,179
1,183
862.8
769
1,132
3,045
2,939
15.1%
23Short-term investments
506.3
341
519.2
242.4
337.8
219.4
604
446.3
500.5
930.7
1,288
9.8%
24Accounts receivable
371.8
414.6
479.3
537.3
599.1
602.8
664.9
699.1
828.1
727.4
912.1
9.4%
25Other current assets
167.9
157.7
177.5
186.1
227.1
283.3
322.3
305.9
671.3
495.4
473.8
10.9%
26Inventory
339.9
396.6
554.9
607
640.9
802.3
726.7
875.5
903.5
1,087
1,126
12.7%
27Total Current Assets
2,048
2,240
2,532
2,287
2,984
3,091
3,181
3,096
4,036
6,285
6,739
12.7%
Non-Current Assets
28Net property, plant & equipment
482.5
580
679.7
867.5
1,140
1,489
1,639
1,725
1,675
1,784
1,915
14.8%
29Long-term investments
379.9
532.1
567
506.3
585.5
801.6
1,834
1,239
583.9
307.9
773.9
7.4%
30Other non-current assets
1,149
1,158
1,918
1,663
1,778
1,855
1,849
2,233
3,068
4,678
4,270
14%
31Total Non-Current Assets
2,011
2,270
3,164
3,037
3,504
4,146
5,322
5,197
5,328
6,770
6,958
13.2%
Total Assets
4,059
4,510
5,697
5,324
6,488
7,237
8,503
8,293
9,363
13,055
13,697
12.9%
LIABILITIES
Current Liabilities
32Accounts payable
63.9
97.1
116.6
134
180.4
196.5
204.5
201.9
186.6
197.4
227.5
13.5%
33Short-term debt
-
-
598
-
25.5
27.2
25.5
25.5
22.9
23.4
24.5
(32.9)%
34Other current liabilities
412.3
435.4
684.8
742.6
696.5
670.2
802.3
795
985.9
1,284
1,562
14.3%
35Total Current Liabilities
476.2
532.5
1,399
876.6
902.4
893.9
1,032
1,022
1,195
1,505
1,814
14.3%
Non-Current Liabilities
36Long-term debt
596.9
822.3
438.4
593.8
653.3
667.7
664.8
665.8
662.2
676.6
680.9
1.3%
37Other non-current liabilities
483.1
536.2
864
712.9
784.1
1,101
969.6
797.6
786.2
810.6
865
6%
38Total Non-Current Liabilities
1,080
1,359
1,302
1,307
1,437
1,769
1,634
1,463
1,448
1,487
1,546
3.7%
39Total Liabilities
1,556
1,891
2,702
2,183
2,340
2,663
2,667
2,486
2,644
2,992
3,360
8%
SHAREHOLDERS` EQUITY
40Common stock
239.1
242.6
212
215.2
218.1
636.4
642
646.3
650.5
654.8
658.7
10.7%
41Retained earnings / (deficit)
3,337
3,906
2,001
2,695
3,742
4,565
6,068
7,590
8,992
13,167
14,241
15.6%
42Accumulated other comprehensive income / (loss)
(182.6)
(198.4)
(132.7)
(138.5)
(156)
(161.1)
(157.7)
(254.9)
(242.8)
(244.5)
(238.3)
2.7%
43Noncontrolling interests
-
-
-
-
-
-
-
-
69.4
64.5
-
(7.1)%
44Total shareholders' equity
2,503
2,619
2,995
3,140
4,148
4,574
5,836
5,807
6,719
10,063
10,338
15.2%
45Total Liabilities and shareholders' Equity
4,059
4,510
5,697
5,324
6,488
7,237
8,503
8,293
9,363
13,055
13,697
12.9%
46Total Debt
596.9
822.3
1,036
593.8
678.8
694.9
690.3
691.3
685.1
700
705.4
1.7%
47Net Debt
(121.5)
(107.8)
218.1
(120.3)
(500.3)
(488.3)
(172.5)
(77.7)
(447.2)
(2,345)
(2,233)
33.8%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
494.9
569.5
622.1
722.2
1,047
823.4
1,503
1,522
1,402
4,175
1,074
8.1%
49Depreciation & amortization
65.8
71.2
81.9
77.4
89.3
107.2
134.8
139.6
144.9
155.2
156.6
9.1%
50Share-based compensation expense
49.9
56.9
61.6
71
81.3
92.6
109.3
126.8
139.4
162.3
158.1
12.2%
51Changes in working capital and other assets
(60.9)
6.8
235.1
56.2
(38.1)
31.1
(15.1)
(570.1)
(790.9)
(3,950)
207
-
52Net cash flows from operating activities
549.7
704.4
1,001
926.8
1,179
1,054
1,732
1,218
895.8
542.3
1,595
11.2%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(106.5)
(217.4)
(175.5)
(241.7)
(278.4)
(407.3)
(329.8)
(264.8)
(266.3)
(282.4)
(260.2)
9.3%
54Purchases of investments / marketable securities
(1,318)
(1,075)
(1,347)
(471.9)
(603.1)
(861.7)
(1,892)
(778.9)
(105.5)
(945.8)
(3,135)
9.1%
55Proceeds from maturities of marketable securities
1,440
1,085
1,103
801.3
409.9
777
529.2
1,359
715.8
857.6
2,878
7.2%
56Other investing activities
(331.3)
(4.5)
(227.7)
(11)
(124.2)
(39.1)
(29.5)
(63.1)
(170.2)
2,684
(195.7)
(5.1)%
57Net cash flows from investing activities
(316.1)
(211.7)
(647.2)
76.7
(595.8)
(531.1)
(1,723)
252.3
173.8
2,313
(712.9)
8.5%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(192.9)
(559)
(649.5)
(648.5)
(102.8)
(625.4)
(512.8)
(1,727)
(879.6)
(1,159)
(719.3)
14.1%
59Dividends paid, net
-
-
-
-
-
-
-
-
-
-
-
-
60Debt issuance (repayments), net
1.9
222.1
176.3
(437.3)
(10)
(0.8)
(1.8)
(0.2)
(0.3)
-
-
-
61Other financing activities
32.4
68.4
-
(15.4)
(2.8)
139.3
158.3
142.8
168.9
176.4
(237.5)
-
62Net cash flows from financing activities
(158.6)
(268.5)
(473.2)
(1,101)
(115.6)
(486.9)
(356.3)
(1,585)
(711)
(983)
(956.8)
19.7%
63Increase (decrease) in cash and cash equivalents
64.6
211.7
(111.8)
(104.2)
465
15.8
(332.8)
(94.8)
375.4
1,911
(119.3)
-
64Cash and equivalents, ending balance
718.4
930.1
818.3
714.1
1,179
1,200
867.4
772.6
1,148
3,059
2,940
15.1%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
443.2
487
825.2
685.1
901
647
1,402
953.4
629.5
259.9
1,335
11.7%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Edwards Lifesciences (EW) financial statements and performance

Explore Edwards Lifesciences (EW) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.